KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Deffered Revenue (2016 - 2022)

Historic Non-Current Deffered Revenue for Pacira BioSciences (PCRX) over the last 10 years, with Q1 2022 value amounting to $10.1 million.

  • Pacira BioSciences' Non-Current Deffered Revenue changed N/A to $10.1 million in Q1 2022 from the same period last year, while for Mar 2022 it was $10.1 million, marking a year-over-year change of. This contributed to the annual value of $10.1 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that Pacira BioSciences reported Non-Current Deffered Revenue of $10.1 million as of Q1 2022.
  • In the past 5 years, Pacira BioSciences' Non-Current Deffered Revenue ranged from a high of $10.1 million in Q4 2021 and a low of $10.1 million during Q4 2021